Spallarossa P - Search Results

1

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism.

Masini M, Toma M, Spallarossa P, Porto I, Ameri P. Masini M, et al. Among authors: spallarossa p. Curr Oncol Rep. 2023 Sep;25(9):979-987. doi: 10.1007/s11912-023-01428-y. Epub 2023 Jun 6. Curr Oncol Rep. 2023. PMID: 37278934 Free PMC article. Review.

2

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy.

Spallarossa P, Sarocchi M, Tini G, Arboscello E, Toma M, Ameri P, Porto I. Spallarossa P, et al. Front Pharmacol. 2020 Jun 26;11:972. doi: 10.3389/fphar.2020.00972. eCollection 2020. Front Pharmacol. 2020. PMID: 32676031 Free PMC article. Review.

3

Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation.

Toma M, Rrapaj E, Spallarossa P, Guerra F, Ameri P. Toma M, et al. Among authors: spallarossa p. Eur J Intern Med. 2020 Dec;82:128-129. doi: 10.1016/j.ejim.2020.08.004. Epub 2020 Aug 5. Eur J Intern Med. 2020. PMID: 32771270 No abstract available.

4

Cardiovascular safety of the tyrosine kinase inhibitor nintedanib.

Ameri P, Tini G, Spallarossa P, Mercurio V, Tocchetti CG, Porto I. Ameri P, et al. Among authors: spallarossa p. Br J Clin Pharmacol. 2021 Oct;87(10):3690-3698. doi: 10.1111/bcp.14793. Epub 2021 Mar 8. Br J Clin Pharmacol. 2021. PMID: 33620103 Free article. Review.

5

Diversity of Cardiologic Issues in a Contemporary Cohort of Women With Breast Cancer.

Tini G, Ameri P, Buzzatti G, Sarocchi M, Murialdo R, Guglielmi G, Arboscello E, Ballestrero A, Del Mastro L, Spallarossa P, Porto I. Tini G, et al. Among authors: spallarossa p. Front Cardiovasc Med. 2021 Oct 1;8:654728. doi: 10.3389/fcvm.2021.654728. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34660706 Free PMC article.

6

Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.

Tini G, Cuomo A, Battistoni A, Sarocchi M, Mercurio V, Ameri P, Volpe M, Porto I, Tocchetti CG, Spallarossa P. Tini G, et al. Among authors: spallarossa p. Int J Cardiol. 2022 Feb 15;349:134-137. doi: 10.1016/j.ijcard.2021.11.059. Epub 2021 Nov 27. Int J Cardiol. 2022. PMID: 34848212

7

Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?

Tini G, Sarocchi M, Ameri P, Tocci G, Battistoni A, Arboscello E, Spallarossa P, Porto I. Tini G, et al. Among authors: spallarossa p. J Cardiovasc Med (Hagerstown). 2022 Dec 1;23(12):809-810. doi: 10.2459/JCM.0000000000001346. J Cardiovasc Med (Hagerstown). 2022. PMID: 36349946 No abstract available.

8

Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program.

Tini G, Sarocchi M, Sirello D, Murialdo R, Fornarini G, Buzzatti G, Boccardo F, Arboscello E, Porto I, Ameri P, Spallarossa P. Tini G, et al. Among authors: spallarossa p. Eur J Prev Cardiol. 2021 Aug 9;28(9):e38-e40. doi: 10.1177/2047487320923056. Eur J Prev Cardiol. 2021. PMID: 32375549 No abstract available.

9

[No title available]

[No authors listed] [No authors listed] PMID: 33611422

10

Cardiac toxicity of trastuzumab in elderly patients with breast cancer.

Denegri A, Moccetti T, Moccetti M, Spallarossa P, Brunelli C, Ameri P. Denegri A, et al. Among authors: spallarossa p. J Geriatr Cardiol. 2016 May;13(4):355-63. doi: 10.11909/j.issn.1671-5411.2016.04.003. J Geriatr Cardiol. 2016. PMID: 27403145 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120 results

Search Page